Log in

TXTM ProText Mobility, Inc. OTC · United States

ProText Mobility (TXTM) news

ProText Mobility, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker TXTM, recorded under United States. The directory classifies it as Mixed biopharma / other operations. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest ProText Mobility news

We have not published a story on ProText Mobility yet. When there is news, it will appear here.

Questions about ProText Mobility

What is the ticker symbol of ProText Mobility?

ProText Mobility, Inc. trades under the ticker TXTM on OTC.

Where is ProText Mobility listed?

ProText Mobility, Inc. is listed on OTC.

Which country or territory is ProText Mobility listed under?

Our directory records ProText Mobility, Inc. under United States.

What does ProText Mobility do?

Our directory classifies ProText Mobility, Inc. as: Mixed biopharma / other operations. This is a directory classification, not a description of the pipeline.

What is the ISIN of ProText Mobility?

The ISIN recorded for ProText Mobility, Inc. is US74371E2046.

Does aibio.space cover ProText Mobility?

aibio.space lists ProText Mobility, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to ProText Mobility?

Companies in our directory listed in the same country and business area as ProText Mobility: Aspire-Lakewood Holdings, GOLDENWELL BIOTECH INC., Niagen Bioscience, Herborium Group, Applied Biosciences, America Great Health.

Investor discussion: ProText Mobility

Members talk about ProText Mobility (TXTM). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:TXTM on TradingView.

Listing details

ProText Mobility, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker TXTM, recorded under United States. The directory classifies it as Mixed biopharma / other operations. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
ProText Mobility, Inc.
Ticker
TXTM
Listing
OTC
Country or territory
United States
Business scope
Mixed biopharma / other operations
ISIN
US74371E2046
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.